

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis of Double Headed Imidazoline Acyclo C-Nucleosides: 1,4-bis[1-Amino-5-oxo-4-Substituted-(Imidazolin-2-yl)]galacto-tetritols

Adel Z. Nasr^a

^a Department of Chemistry, Faculty of Science, Cairo University, Faiyoun, Egypt

Online publication date: 05 December 2003

To cite this Article Nasr, Adel Z.(2003) 'Synthesis of Double Headed Imidazoline Acyclo C-Nucleosides: 1,4-bis[1-Amino-5-oxo-4-Substituted-(Imidazolin-2-yl)]galacto-tetritols', *Nucleosides, Nucleotides and Nucleic Acids*, 22: 3, 349 — 357

To link to this Article: DOI: 10.1081/NCN-120021433

URL: <http://dx.doi.org/10.1081/NCN-120021433>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Synthesis of Double Headed Imidazoline Acyclo C-Nucleosides: 1,4-bis[1-Amino-5-oxo-4-Substituted- (Imidazolin-2-yl)]galacto-tetritols

Adel Z. Nasr*

Department of Chemistry, Faculty of Science, Cairo University,
Faiyoum, Egypt

ABSTRACT

Condensation of 2,3,4,5-tetra-*O*-acetyl-galactaroyl dichloride (**1**) with two equivalents of the α -amino esters **2a–c** gave the corresponding 2,3,4,5-tetra-*O*-acetyl-galactaric acid diamides **3a–c**. Heterocyclization of **3a–c** by heating with hydrazine hydrate took place with concomitant de-*O*-acetylation of the poly-acetoxyalkyl chain to give 1,4-bis[1-amino-5-oxo-4-substituted(imidazolin-2-yl)]galacto-tetritols (**5a–c**) and not the theoretically possible 1,2,4-triazinones **4** as indicated by spectral data. Compounds **5a–c** readily reacted with *p*-nitrobenzaldehyde to give the corresponding *p*-nitrobenzylideneamino derivatives **6a–c**. Acetylation of **5a–c** afforded the 2,3,4,5-tetra-*O*-acetyl-1,4-bis[1-acetamido-5-oxo-4-substituted(imidazolin-2-yl)]galacto-tetritols (**7a,b,d**). De-*O*-acetylation of **7a,b,d** gave 1,4-bis[1-acetamido-5-oxo-4-substituted (imidazolin-2-yl)]galacto-tetritols (**8a–c**).

*Correspondence: Adel Z. Nasr, Department of Chemistry, Faculty of Science, Cairo University, Faiyoum 63514, Egypt; E-mail: Adelnasr@hotmail.com.



INTRODUCTION

Imidazole acyclo *C*-nucleosides constitute an important class of acyclo *C*-nucleosides^[1–6] especially after the isolation and characterization of the naturally occurring imidazole acyclo *C*-nucleoside antibiotic CV-1 [5-hydroxy-(*D*-arabino-tetritol-1-yl)imidazolidin-2-one] from a strain of *Streptomyces* sp.II.^[7] Accordingly, considerable efforts have been directed toward the synthesis of many imidazole acyclo *C*-nucleosides seeking their diverse biological activities.^[1–6] Members of imidazole acyclo *C*-nucleosides were found to produce lymphopenia,^[8] depress blood lymphocyte counts in both mice and rats,^[9] prevent spontaneous and cyclophosphamide-induced diabetes in non-obese diabetic mice^[10] as well as possess protein kinase inhibition.^[11] Moreover, multitudinous pharmaceutical activities^[12–18] and agrochemical applications^[19–21] were attributed to compounds comprising imidazole rings. These aspects prompted us to investigate a novel approach for the synthesis of the title double headed imidazoline acyclo *C*-nucleosides as a part of a program directed towards the synthesis of acyclo *C*-nucleosides.^[22–25]

RESULTS AND DISCUSSION

Condensation of one molar equivalent of 2,3,4,5-tetra-*O*-acetyl-galactaroyl dichloride (**1**)^[26] with two molar equivalents of three α -amino esters, namely: glycine ethyl ester (**2a**), L-phenylalanine methyl ester (**2b**) and L-tyrosine methyl ester (**2c**) hydrochlorides gave products which showed three IR absorptions characteristic of NH, ester and amide carbonyls. The products correctly analysed for the 2,3,4,5-tetra-*O*-acetyl-galactaric acid diamide structures **3a–c**. Each product exhibited ¹H NMR signals of two exchangeable NH protons, four tetritolyl chain protons and four *O*-acetyl group protons. Compound **3a** showed in addition, two ethyl group protons and two methylene protons while compounds **3b** and **3c** showed the expected two benzyl group protons, two CH protons and two methyl group protons (compound **3c** showed also two broad exchangeable OH protons).

Subjecting compound **3a** to heterocyclization by heating with hydrazine hydrate, gave a single crystalline product which revealed IR absorptions at 3310 (OH and NH), 1663 (CON) and 1618 cm^{–1} (C=N) and lacked the ester carbonyl absorptions of the parent **3a**. The cyclization product correctly analysed for the molecular formula C₁₀H₁₆N₆O₆ indicating that heterocyclization took place with concomitant hydrazinolytic de-*O*-acetylation of the sugar chain. Accordingly, it may possess the 1,4-bis[2,5-dihydro-6-oxo-1H-(1,2,4-triazin-3-yl)]galacto-tetritol (**4**) or the 1,4-bis[1-amino-5-oxo-(imidazolin-2-yl)]galacto-tetritol (**5a**) structure. However the product was assigned the imidazolinone structure **5a** rather than the 1,2,4-triazinone structure **4** on the bases of the following evidence. First, the appearance of the two amino groups of **5a** as one singlet signal at δ 8.61. Had structure **4** been obtained, two separate NH proton signals would have appeared as double one-proton signals at δ 10–11.5 and δ 6.9–7.5 ppm.^[27–29] Second, the ease of condensation of the amino group of **5a** with *p*-nitrobenzaldehyde to afford the corresponding *p*-nitrobenzylideneamino derivative **6a**. The alternative 1,2,4-triazinone structure **4** would not undergo such a reaction.

Similarly, the diamides **3b,c** were heterocyclized by heating with hydrazine hydrate to the corresponding double headed acyclo C-nucleosides **5b,c**. The mass spectrum of **5b** did not show its molecular ion peak, yet revealed peaks for the alditolyl chain C1–C2 cleavage. The spectrum showed a fragment at m/z 217 corresponding to the heterocyclic base carrying a protonated formyl group characterising C-nucleoside structures.^[30] Condensation of compounds **5b** or **5c** with *p*-nitrobenzaldehyde afforded the corresponding *p*-nitro-benzylideneamino derivatives **6b** and **6c**.

Treatment of **5a–c** with acetic anhydride in the presence of pyridine at room temperature caused acetylation of the hydroxy groups as well as the imidazoline amino group to give the 2,3,4,5-tetra-*O*-acetyl-1,4-bis[1-acetamido-5-oxo-4-substituted(imidazolin-2-yl)]galacto-tetritols **7a,b,d**. IR spectra of the latter compounds showed OAc, CON and C=N absorptions. The ¹H NMR spectra of the prepared compounds showed two exchangeable NH protons, four tetritolyl chain protons, two acetamido methyl protons and four acetoxy methyl protons (compound **7d** showed two additional aryloxy acetyl group protons), in addition compound **7a** showed two imidazoliny CH₂ protons while compounds **7b** and **7d** showed the expected two benzyl group protons and two imidazoliny CH protons. The mass spectrum of **7b** showed the characteristic protonated formyl heterocyclic fragment at m/z 260.

De-*O*-acetylation of **7a,b,d** with a solution of ammonium hydroxide and methanol gave the corresponding 1,4-bis[1-acetamido-5-oxo-4-substituted (imidazolin-2-yl)]galacto-tetritols **8a–c** which showed (OH and NH), (CON) and (C=N) IR absorptions.

EXPERIMENTAL

Melting points were determined on MEL-TEMP II melting point apparatus in open glass capillaries and are uncorrected. The infrared spectra IR were recorded for potassium bromide discs on a Pye-Unicam SP1025 spectrophotometer. Proton magnetic resonance ¹H NMR spectra were carried out at ambient temperature (~25°C) with a Varian EM-390 or with a Bruker AC-250 spectrometers using tetramethylsilane (TMS) as an internal standard. Mass spectra (MS) were performed on a Hewlett-Packard 5995 gas chromatography-mass spectrometer system. Homogeneity of the products and follow up of the reactions were checked by ascending thin-layer chromatography TLC on plates precoated with silica gel G (E. Merck; layer thickness 0.25 mm), used without pretreatment. All ratios of the used solvent systems were volume to volume V/V, the solvent system used were: (A) CHCl₃/MeOH (9:1) and (B) CHCl₃/MeOH (1:1); the distance of the solvent travel was 5 cm and the spots were visualised by exposure to iodine vapour for a few minutes. Elemental microanalyses were performed at the Microanalytical Unit, Cairo University, Cairo, Egypt.

General Procedure for the Preparation of 2,3,4,5-Tetra-*O*-acetyl-galactaric acid diamides (3a–c**).** A solution of **1** (5 mmol) in dry benzene (30 mL) was gradually added to a stirred solution of the appropriate α -amino ester hydrochloride



(**2a–c**, 10 mmol) in dry pyridine (15 mL) at ambient temperature. After stirring for 3 h, the solvents were evaporated under reduced pressure and the syrupy residue was crystallised from EtOH. The following compounds were prepared:

2,3,4,5-Tetra-O-acetyl-galactaric acid di(glycine ethyl ester)amide(3a). Colorless crystals; Yield: 70%; m.p.: 198–200°C; TLC: (A), R_f : 0.51; IR: 3244 (NH), 1755 (ester C=O) and 1678 cm^{-1} (CON); ^1H NMR (CDCl_3): δ 9.61 (s, 2 H, exchangeable, 2 NH), 6.26, 5.50 (2s, 2 H each, tetritoldi-1,4-yl 4 H), 4.78 (q, 4 H, 2 CH_2CH_3), 3.31 (s, 4 H, 2 CH_2), 2.18, 2.15 (2 s, 6 H each, 4 OAc), 1.24 (t, 6 H, 2 CH_2CH_3).

Anal. Calcd. for $\text{C}_{22}\text{H}_{32}\text{N}_2\text{O}_{14}$: C, 48.2; H, 5.8; N, 5.1. Found: C, 48.3; H, 5.9; N, 5.1.

2,3,4,5-Tetra-O-acetyl-galactaric acid di(phenylalanine methyl ester)amide(3b). Colorless crystals; Yield: 78%; m.p.: 206–208°C; TLC: (A), R_f : 0.53; IR: 3277 (NH), 1759 (ester C=O) and 1665 cm^{-1} (CON); ^1H NMR (CD_3): δ 9.86 (s, 2 H, exchangeable, 2 NH), 7.66–7.14 (m, 10 H, ArH), 5.65, 5.37 (2 s, 2 H each, tetritoldi-1,4-yl 4H), 5.06–4.81 (m, 2 H, CONHCH), 4.16–3.98 (m, 4 H, 2 benzyl CH_2), 3.75 (s, 6 H, 2 OCH_3), 2.28, 2.19 (2 s, 6H, 4 OAc).

Anal. Calcd. for $\text{C}_{34}\text{H}_{40}\text{N}_2\text{O}_{14}$: C, 58.3; H, 5.7; N, 4.0. Found: C, 58.4; H, 5.6; N, 4.0.

2,3,4,5-Tetra-O-acetyl-galactaric acid di(Tyrosine methyl ester)amide (3c). Colorless crystals; Yield: 75%; m.p.: 220–222°C. TLC: (A), R_f : 0.49; IR: 3430 (OH), 3319 (NH), 1764 (ester C=O), and 1676 cm^{-1} (C=N); ^1H NMR [$(\text{CD}_3)_2\text{SO}$]: δ 9.93 (s, 2 H, exchangeable, 2 NH), 7.23–6.85 (m, 8 H, ArH), 5.85, 5.45 (2 d, 2 H each, tetritoldi-1,4-yl, 5.16–4.99, (m, 2 H, CONHCH), 4.46 (s, broad, 2 H, exchangeable, 2 OH) 4.11–3.92 (m, 4 H, 2 benzy CH_2), 3.74 (s, 6 H, 2 OCH_3), 2.28, 2.09 (2 s, 6 H, 4 OAc).

Anal. Calcd. for $\text{C}_{34}\text{H}_{40}\text{N}_2\text{O}_{16}$: C, 55.7; H, 5.5; N, 3.8. Found: C, 55.7; H, 5.4; N, 3.9.

General Procedure for the Preparation of 1,4-Bis(1-amino-5-oxo-4-substituted (imidazolin-2-yl)]galacto-tetritols (5a–c). A mixture of the particular diamide (**3a–c**, 1 mmol) and hydrazine hydrate (50 mL) was heated at reflux for 4 h and then evaporated under reduced pressure. The obtained residue was crystallized from a $\text{H}_2\text{O}/\text{MeOH}$ -mixture. The following compounds were prepared:

1,4-Bis[1-amino-5-oxo-(imidazolin-2-yl)]galacto-tetritol(5a). Colorless crystals; Yield: 61%; m.p.: 266–270°C/dec.; TLC: (B), R_f : 0.52; IR: 3310 (broad, OH + NH), 1663 (CON), and 1618 cm^{-1} (C=N); ^1H NMR [$(\text{CD}_3)_2\text{SO}$]: δ 8.61 (s, 4 H, exchangeable, 2 NH_2), 5.10, 4.40 (2 s, broad, exchangeable, 2 OH each), 4.18, 3.76 (2 d, 2 H each, tetritoldi-1,4-yl 4 H), 3.29 (s, 4 H, 2 imidazoliny CH_2).

Anal. Calcd. for $\text{C}_{10}\text{H}_{16}\text{N}_6\text{O}_6$: C, 38.0; H, 5.1; N, 26.6. Found: C, 38.2; H, 5.0; N, 26.5.

1,4-Bis[1-amino-4-benzyl-5-oxo-(imidazolin-2-yl)]galacto-tetritol (5b). Colorless crystals; Yield: 67%; m.p.: 238–240°C/dec.; TLC: (B), R_f : 0.49; IR: 3376, 3320

(OH), 3182 (NH), 1661 (CON), and 1604 cm^{-1} (C=N); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: δ 8.79 (s, 4 H, exchangeable, 2 NH_2), 7.91–6.61 (m, 12 H, 10 ArH, 2 imidazolinyl H), 5.71, 5.39 (2 d, exchangeable, 2 OH each), 4.97, 4.61 (2 s, 2 H each, tetritoldi-1,4-yl 4 H), 4.52 (s, 4 H, 2 benzyl CH_2).

Anal. Calcd. for $\text{C}_{24}\text{H}_{28}\text{N}_6\text{O}_6$: C, 58.1; H, 5.7; N, 16.9. Found: C, 58.2; H, 5.7; N, 16.9.

1,4-Bis[1-amino-4-(p-hydroxybenzyl)-5-oxo-(imidazolin-2-yl)]galacto-tetritol (5c). Colorless crystals; Yield: 63%; m.p.: 300–304°C/dec; TLC: (B), R_f : 0.47; IR: 3327 (broad, OH + NH), 1665 (CON), and 1618 cm^{-1} (C=N); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: δ 8.81 (s, 4 H, exchangeable, 2 NH_2), 7.84–6.53 (m, 10 H, 8 ArH, 2 imidazolinyl H), 5.51, 5.23 (2 d, exchangeable, 2 OH each), 4.99 (s, broad, 2 H, exchangeable 2 OH), 4.81, 4.69 (2 s, 2 H each, tetritoldi 1,4-yl 4 H), 4.41 (s, 4 H, 2benzyl CH_2).

Anal. Calcd. for $\text{C}_{24}\text{H}_{28}\text{N}_6\text{O}_8$: C, 54.5; H, 5.3; N, 15.9. Found: C, 54.6; H, 5.2; N, 15.8.

General Procedure for the Preparation of p-Nitrobenzylideneamino derivatives(6a–c).

A solution of the particular **5a–c** (0.5 mmol) in H_2O (15 mL) was treated with a solution of *p*-nitrobenzaldehyde (0.5 mmol) in ethanol (25 mL) and the mixture was heated at 100°C for 30 min. The product which separated after attaining ambient temperature was filtered and crystallized from a H_2O /MeOH – mixture. The following compounds were prepared:

1,4-Bis[1-(p-nitrobenzylideneamino)-5-oxo-(imidazolin-2-yl)]galacto-tetritol(6a). Pale yellow crystals; Yield: 72%; m.p.: 238–240°C; TLC: (B), R_f : 0.50; IR: 3361 (broad, OH), 1681 (CON), 1645, and 1629 cm^{-1} (C=N); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: δ 8.20–7.81 (m, 10 H, 8 ArH, 2 $\text{CH}=\text{N}$), 5.23, 4.64 (2 d, exchangeable 2 OH each), 4.59, 4.19 (2 d, 2 H each, tetritoldi-1,4-yl 4 H), 3.49 (s, 4 H, 2 imidazolinyl CH_2).

Anal. Calcd. for $\text{C}_{24}\text{H}_{22}\text{N}_8\text{O}_{10}$: C, 49.5; H, 3.8; N, 19.2. Found: C, 49.5; H, 3.9; N, 19.3.

1,4-Bis[1-(p-nitrobenzylideneamino)-4-benzyl-5-oxo-(imidazolin-2-yl)] galacto-tetritol(6b). Pale yellow crystals; Yield: 68%; m.p. 226–228°C/dec.; TLC: (B), R_f : 0.47; IR: 3393 (broad, OH), 1679 (CON), 1645, and 1627 cm^{-1} (C=N); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: δ 8.37–7.82 (m, 18 H, ArH), 7.32–6.84 (m, 4 H, 2 $\text{CH}=\text{N}$, 2 imidozolinyl H), 5.74, 5.34 (2 d, exchangeable 2 OH each), 4.93, 4.54 (2 s, 2 H each, tetritoldi-1,4-yl 4 H), 4.31 (s, 4 H, 2 benzyl CH_2).

Anal. Calcd. for $\text{C}_{38}\text{H}_{34}\text{N}_8\text{O}_{10}$: C, 59.8; H, 4.5; N, 14.7. Found: C, 59.9; H, 4.4; N, 14.8.

1,4-Bis[1-(p-nitrobenzylideneamino)-4-(p-hydroxybenzyl)-5-oxo-(imidazolin-2-yl)] galacto-tetritol (6c). Pale yellow crystals; Yield: 62%; m.p. 268–270°C/dec.; TLC: (B), R_f : 0.45; IR: 3329 (broad, OH), 1678 (CON), 1646, and 1628 cm^{-1} (C=N); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: δ 8.54–7.58 (m, 16 H, ArH), 7.21–6.90 (m, 4 H, 2 $\text{CH}=\text{N}$, 2 imidazolinyl H), 5.67, 5.29 (2 d, exchangeable 2 OH each), 5.01 (s, broad, 2 H, exchangeable, 2 OH), 4.88, 4.39 (2 s, 2 H each, tetritoldi-1,4-yl 4 H), 4.21 (s, 4 H, 2 benzyl CH_2).



Anal. Calcd. for $C_{38}H_{34}N_8O_{12}$: C, 57.4; H, 4.3; N, 14.1. Found: C, 57.4; H, 4.3; N, 14.0.

General Procedure for the Preparation of 2,3,4,5-Tetra-O-acetyl-1,4-bis[1-acetamido-5-oxo-4-substituted(imidazolin-2-yl)]galacto-tetritols (7a,b,d). A mixture of the respective **5a–c** (5 mmol) in pyridine (5 mL) and acetic anhydride (25 mL) was stirred for 24 h at ambient temperature. The mixture was evaporated under reduced pressure and the residue was crystallized from EtOH. The following compounds were prepared:

2,3,4,5-Tetra-O-acetyl-1,4-bis[1-acetamido-5-oxo-(imidazolin-2-yl)] galacto-tetritol (7a). Colorless crystals; Yield: 71%; m.p.: 260–261°C/dec.; TLC: (A), R_f : 0.55; IR: 3459 (NH), 1741 (OAc), 1662 (CON), and 1645 cm^{-1} (C=N); 1H NMR ($CDCl_3$): δ 13.20 (s, 2 H, exchangeable, 2 NH), 6.47, 5.87 (2 s, 2 H each, tetritol-di-1,4-yl-4 H), 3.33 (s, 4 H, 2 imidazolinyll CH_2), 2.47 (s, 6 H, 2 NAc), 2.19, 2.09 (2 s, 6 H each, 4 OAc).

Anal. Calcd. for $C_{22}H_{28}N_6O_{12}$: C, 46.5; H, 4.9; N, 14.8. Found: C, 46.6; H, 4.8; N, 14.7.

2,3,4,5-Tetra-O-acetyl-1,4-bis[1-acetamido-4-benzyl-5-oxo-(imidazolin-2-yl)]galacto-tetritol (7b). Colorless crystals; Yield: 68%; m.p.: 250–251°C/dec.; TLC: (A), R_f : 0.53; IR: 3440 (OH), 1740 (OAc), 1675 (CON), and 1642 cm^{-1} (C=N); 1H NMR ($CDCl_3$): δ 13.09 (s, 2 H, exchangeable, 2 NH), 7.42–6.98 (m, 12 H, 10 ArH, 2 imidazolinyll H), 6.54, 5.73 (2 s, 2 H each, tetritol-di-1,4-yl 4 H), 4.11 (d, 4 H, 2 benzyl CH_2), 2.54 (s, 6 H, 2 NAc), 2.13, 2.01 (2 s, 5 H each, 4 OAc).

Anal. Calcd. for $C_{36}H_{40}N_6O_{12}$: C, 57.8; H, 5.4; N, 11.2. Found: C, 57.7; H, 5.4; N, 11.1.

2,3,4,5-Tetra-O-acetyl-1,4-bis[1-acetamido-4-(p-acetoxybenzyl)-5-oxo-(imidazolin-2-yl)]galacto-tetritol (7d). Colorless crystals; Yield: 65%; m.p.: 254–255°C/dec.; TLC: (A), R_f : 0.51; IR: 3460 (NH), 1741 (OAc), 1663 (CON), and 1644 cm^{-1} (C=N); 1H NMR ($CDCl_3$): δ 13.31 (s, 2 H, exchangeable, 2 NH), 7.62–7.27 (m, 10 H, 8 ArH, 2 imidazolinyll H), 6.67, 5.65 (2 s, 2 H each, tetritol-di-1,4-yl 4 H), 4.40 (d, 4 H, 2 benzyl CH_2), 2.20 (s, 6 H, 2 NAc), 2.11, 2.08, 2.04 (3 s, 6 H each, 6 OAc).

Anal. Calcd. for $C_{40}H_{44}N_6O_{10}$: C, 55.6; H, 5.1; N, 9.7. Found: C, 55.7; H, 5.0; N, 9.8.

General Procedure for the Preparation of 1,4-Bis[1-acetamido-5-oxo-4-substituted-(imidazolin-2-yl)]galacto-tetritols (8a–c). A solution of the appropriate **7a,b,d** (2 mmol) in methanol (50 mL) was treated with 20% aqueous NH_3 solution (15 mL) and kept at ambient temperature for 24 h. Evaporation of the solvent under reduced pressure gave a residue which crystallized from a $H_2O/MeOH$ – mixture. The Following compounds were prepared:

1,4-Bis[1-acetamido-5-oxo-(imidazolin-2-yl)]galacto-tetritol (8a). Colorless crystals; Yield: 57%; m.p.: 328–330°C/dec.; TLC: (B), R_f : 0.58; IR: 3439 (broad OH + NH), 1694 (CON) and 1645 cm^{-1} (C=N); 1H NMR [$(CD_3)_2SO$]: δ 13.14



(s, 2 H, exchangeable, 2 NH), 5.53, 4.91 (2 d, exchangeable, 2 OH each), 4.77, 3.80 (2 d, 2 H each, tetritoldi-1,4-yl 4 H), 3.53 (s, 4 H, 2 imidazoliny CH₂), 2.89 (s, 6 H, 2 NAc).

Anal. Calcd. for C₁₄H₂₀N₆O₈: C, 42.0; H, 5.0; N, 21.0. Found: C, 42.1; H, 5.0; N, 21.1.

1,4-Bis[1-acetamido-4-benzyl-5-oxo-(imidazolin-2-yl)]galacto-tetritol(8b). Colorless crystals; Yield: 61%; m.p.: >350°C; TLC: (B), R_f: 0.56; IR: 3301 (broad OH + NH), 1694 (CON), and 1600 cm⁻¹ (C=N); ¹H NMR [(CD₃)₂SO]: δ 13.04 (s, 2 H, exchangeable, 2 NH), 7.37–6.82 (m, 12 H, 10 ArH, 2 imidazoliny H), 5.84, 5.17 (2 d, exchangeable, 2 OH each), 4.83, 4.59 (2 s, 2 H each, tetritoldi-1,4-yl 4 H), 4.39 (s, 4 H, 2 benzyl CH₂), 2.94 (s, 6 H, 2 NAc).

Anal. Calcd. for C₂₈H₃₂N₆O₈: C, 57.9; H, 5.5; N, 14.5. Found: C, 57.9; H, 5.4; N, 14.5.

1,4-Bis[1-acetamido-4-(p-hydroxybenzyl)-5-oxo-imidazolin-2-yl]galacto-tetritol(8c). Colorless crystals; Yield: 64%; m.p.: >350°C; TLC: (B), 0.53; IR: 3442 (broad OH + NH), 1685 (CON), and 1614 cm⁻¹ (C=N); ¹H NMR [(CD₃)₂SO]: δ 13.21 (s, 2 H, exchangeable), 7.21–6.73 (m, 10 H, 8 ArH, 2 imidazoliny H), 5.73, 5.22 (2 d, exchangeable, 2 OH each), 4.92 (s, broad, 2 H, exchangeable 2 OH), 4.71, 4.21 (2 s, 2 H each, tetritoldi-1,4-yl 4 H), 4.09 (s, 4 H, 2 benzyl CH₂), 2.89 (s, 6 H, 2 NAc). Anal. Calcd. for C₂₈H₃₂N₆O₁₆: C, 54.9; H, 5.2; N, 13.7. Found: C, 54.8; H, 5.2; N, 13.8.

REFERENCES

1. Remy, R.J.; Secrist, III, J.A. Acyclic nucleosides other than acyclovir as potential antiviral agents. *Nucleosides Nucleotides* **1985**, 4 (3), 411–427.
2. Chu, C.K.; Cutler, S.J. Chemistry and antiviral activities of acyclonucleosides. *J. Heterocycl. Chem.* **1986**, 23, 289–319.
3. Shaban, M.A.E.; Nasr, A.Z. The chemistry of C-Nucleosides and their analogs I: C-Nucleosides of hetero monocyclic bases. *Adv. Heterocycl. Chem.* **1997**, 68, 223–432.
4. El Ashry, E.S.H.; El Kilany, Y. Acyclonucleosides: Part 1. Seco-nucleosides. *Adv. Heterocycl. Chem.* **1996**, 67, 391–438.
5. El Ashry, E.S.H.; El Kilany, Y. Acyclonucleosides: Part 2. Diseco-nucleosides. *Adv. Heterocycl. Chem.* **1997**, 68, 1–64.
6. El Ashry, E.S.H.; El Kilany, Y. Acyclonucleosides: Part 3. Tri-,tetra-, and penta-seco-nucleosides. *Adv. Heterocycl. Chem.* **1998**, 69, 129–215.
7. Yasuzawa, T.; Yoshida, M.; Ichimura, M.; Shirahata, K.; Sano, H. CV-1, A new antibiotic produced by a strain of streptomyces sp.II. Structure determination. *J. Antibiot.* **1987**, 40 (6), 727–731.
8. Gobin, S.J.P.; Phillips, J.A. Immunosuppressive effect of 2-acetyl-4-tetrahydroxybutylimidazole (THI) in the rat. *Clin. Exp. Immunol.* **1991**, 85 (2), 335–340; *Chem. Abstr.*, **1991**, 115, 206449e.



9. Iscaro, A.; Mackay, I.R.; O'Brien, C. Lymphopenic effects on mice of component of ammonia caramel, 2-acetyl-4(5)-tetrahydroxy-butylimidazole (THI). *Immunol. Cell. Biol.* **1988**, *66* (5&6), 395–402; *Chem. Abstr.* **1989**, *111*, 38125t.
10. Mandel, T.E.; Koulamanda, M.; Mackay, I.R. Prevention of spontaneous and cyclophosphamide-induced diabetes in non-obese diabetic (NOD) mice with oral 2-acetyl-4-tetrahydroxybutylimidazole (THI), a component of caramel coloring III. *Clin. Exp. Immunol.* **1992**, *88* (3), 414–419; *Chem. Abstr.* **1992**, *117*, 62594q.
11. Rohrlé, A.N.; Schmidhammer, H. Syntheses of 1-(1H-Imidazol-2-yl)ethane-1,2-diol derivatives: A novel class of protein kinase C inhibitors. *Helv. Chim. Acta* **1998**, *81*, 1070–1076.
12. Kudzma, L.V.; Turnbull, S.P. Expedient synthesis of 4(5)-[1,(2,3-dimethyl-phenyl)-1H-imidazole, The α 2-adrenergic agonist medetomidine. *Synthesis* **1991**, 1021–1022.
13. Sun, Z.-Y.; Kwon, C.-H.; Wurlpel, J.N.D. Structure- activity study of 5-substituted 1-carbobenzoxo-2-iminohydantoins a potential anticonvulsant agents. *J. Med. Chem.* **1994**, *37*, 2841–2845.
14. Kramer, K.; Elz, S.; Pertz, H.H.; Schunack, W. N^a-Alkylated derivatives of 2-phenylhistamines: Synthesis and in vitro activity of potent histamine H₁-receptor agonists. *Bioorg. Med. Chem. Lett.* **1998**, *8* (18), 2583–2588; *Chem. Abstr.* **1999**, *130*, 3801a.
15. Timmerman, H.; Vander Goot, H. Preparation of Imidazolyl-alkylisothioureas and Related Compounds as Histamine H₃ Receptor Agonists or Antagonists. US Patent 5,837,718, Nov 17, 1998; *Chem. Abstr.* **1999**, *130*, 13989g.
16. Adams, J.L.; Lee, Di; Long, S.A. Preparation of Pyrimidinylimidazoles as CSBP/PK/p38 Kinase Inhibitors. PCT Int. Appl. WO 9,857,966, Dec 23, 1998; *Chem. Abstr.* **1999**, *130*, 66512c.
17. Bhide, R.S.; Ding, C.Z.; Hunt, J.T.; Kim, S.-H.; Leftheris, K. Preparation of Imidazole Containing Quinoline and Benzazepine Derivatives as Inhibitors of Farnesyl Protein Transferase. PCT Int. Appl. WO 9,901,434, Jan 14, 1999; *Chem. Abstr.* **1999**, *130*, 125071b.
18. Elokda, H.; Sulkowski, T.S.; Strike, D.P. Preparation of 2-(Substituted Sulfanyl)-3,5-dihydro-imidazol-4-ones for Increasing HDL Blood Levels. US Patent 5,877,324, Mar 2, 1999; *Chem. Abstr.* **1999**, *130*, 196654m.
19. Andreani, A.; Locatelli, A.; Rambaldi, M. Synthesis and herbicidal properties of 3-(2-oxo-1-imidazolidinyl-iminomethyl)indoles. *J. Heterocycl. Chem.* **1995**, *32*, 49–51.
20. Hagiwara, K.; Iihama, T.; Marumo, S.; Sano, S.; Shimoda, S. Preparation of 2-(2-Pyridyl)imidazole Compounds as Agricultural Fungicides. Jpn Kokai Patent 97/85,879, Dec 8, 1998; *Chem. Abstr.* **1999**, *130*, 66497b.
21. Assmann, L.; Stenzel, K.; Erdelen, C.; Kugler, M. Preparation of Nitrophenyl-sulfonylimidazoles as Fungicides and Pesticides. Ger Patent Offen DE 19,829,740, Jan 28, 1999; *Chem. Abstr.* **1999**, *130*, 125074m.
22. Shaban, M.A.E.; Nasr, A.Z.; Taha, M.A.M. Synthesis of 1,3,4-thiadiazole and 1,2,4-triazole acyclo C-nucleosides. *J. Carbohydr. Chem.* **1995**, *14* (7), 985–994.
23. Shaban, M.A.E.; Nasr, A.Z.; Taha, M.A.M. Synthesis of acyclo C-nucleosides: 6-(D-Glucopentitol-1-yl)-1,2,4-triazolo[3,4-*b*]1,3,4-thiadiazoles and 1,4-Bis(1,2,

- 4-triazolo[3,4-*b*]1,3,4-thiadiazol-6-yl) galacto-tetritols. *Pharmazie* **1995**, *50*, 534–537.
24. Nasr, A.Z. Synthesis of 1,2,4-triazole and imidazole acyclo C-nucleosides. *Alex. J. Pharm. Sci.* **1996**, *10* (2), 139–141; Chem. Abstr. **1996**, *125*, 301457w.
25. Shaban, M.A.E.; Nasr, A.Z.; Morgaan, A.E.A. Synthesis and antimicrobial activity of acyclo C-nucleoside: 3-(alditol-1-yl)-7-oxo-5-phenyl-1,2,4-triazolo [4,3-*a*]pyrimidines. *Pharmazie* **2000**, *55*, 87–93.
26. Lewis, B.A.; Smith, F.; Stephen, A. M. Aldric acids. (13) Galactaric acid and its derivatives. *Methods Carbohydr. Chem.* **1963**, *2*, 38–46.
27. Camparini, A.; Celli, A.M.; Ponticelli, F.; Tedeschi, P Synthesis and structure of dihydro-1,2,4-triazin-6(1H)-ones (1). *J. Heterocycl. Chem.* **1978**, *15*, 1271–1276.
28. Leschinsky, K.L.; Chupp, J.P. Heterocycles from substituted amides. IX. 4,5-Dihydro-1,2,4-triazin-6(1H)-ones from 2-isocyanoacetates and hydrazines. *J. Heterocycl. Chem.* **1980**, *17*, 1621–1622.
29. Rao, T.S.; Revankar, G.R. Synthesis of certain acyclic nucleoside analogs of 1,2,4-triazolo[3,4-*f*][1,2,4]triazine and pyrimido[5,4-*d*]pyrimidine. *Nucleosides Nucleotides* **1995**, *14* (7), 1601–1612.
30. Townsend, L.B.; Robins, R.K. The mass spedra of formycin B and show-domycin. Carbon linked nucleoside antibiotic (1). *J. Heterocycl. Chem.* **1969**, *6*, 459–464.

Received October 8, 2002

Accepted January 27, 2003



